{"id":244155,"date":"2026-09-11T13:44:57","date_gmt":"2026-09-11T08:14:57","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=244155"},"modified":"2026-09-11T13:44:57","modified_gmt":"2026-09-11T08:14:57","slug":"pharma-intermediates-stock-rises-137-percent-in-1-year","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/","title":{"rendered":"This Pharma Intermediates Stock Rises 137% in 1 Year: Can the CDMO Boom Justify the Price?"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Close Rs 3,451.40 (10 Sep 2026). 1Y return approx 136.7%. 52W range Rs 1,302 to Rs 3,740. Market cap approx Rs 28,256 Cr. FY26 PAT up 122%.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Acutaas Chemicals, formerly Ami Organics, returned approximately 136.7% over one year, rising from Rs 1,458.30 on 10 September 2025. The share closed at Rs 3,451.40, with FY26 profit up about 122% and margins near 36%. CDMO growth and new battery and chip chemicals drove the rally, though the stock trades at about 73 times earnings.<\/p>\n<\/div>\n<p>This pharma intermediates stock has returned approximately 136.7% over the past year, placing it among the top 31 performers on a screen of 195 NSE small-cap stocks dated 11 September 2026. The rally in this pharma intermediates stock has been built on profit that more than doubled in FY26, a sharp rise in margins and new businesses in battery and semiconductor chemicals.<\/p>\n<p>The company is <strong><a href='https:\/\/univest.in\/stocks\/acutaas\/ami-organics-ltd-share-price-today'>Acutaas Chemicals Ltd<\/a> (NSE: ACUTAAS)<\/strong>, which was known as Ami Organics until it changed its name on 15 May 2025. The Acutaas Chemicals share closed at Rs 3,451.40 on 10 September 2026, up about 6.5% on the day after a domestic brokerage upgraded it, giving the company a market value of approximately Rs 28,256 crore.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href='https:\/\/univest.in\/user\/log-in'>Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/#How_Much_Has_This_Pharma_Intermediates_Stock_Gained\" title=\"How Much Has This Pharma Intermediates Stock Gained?\">How Much Has This Pharma Intermediates Stock Gained?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/#Why_Did_This_Pharma_Intermediates_Stock_Rise_So_Much\" title=\"Why Did This Pharma Intermediates Stock Rise So Much?\">Why Did This Pharma Intermediates Stock Rise So Much?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/#1_Profit_Growth_Far_Ahead_of_Sales_Growth\" title=\"1. Profit Growth Far Ahead of Sales Growth\">1. Profit Growth Far Ahead of Sales Growth<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/#2_Quarter_After_Quarter_of_Strong_Results\" title=\"2. Quarter After Quarter of Strong Results\">2. Quarter After Quarter of Strong Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/#3_Advanced_Intermediates_and_CDMO_Work\" title=\"3. Advanced Intermediates and CDMO Work\">3. Advanced Intermediates and CDMO Work<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/#4_Battery_and_Semiconductor_Chemicals\" title=\"4. Battery and Semiconductor Chemicals\">4. Battery and Semiconductor Chemicals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/#5_Rising_Foreign_Ownership_and_a_Recent_Upgrade\" title=\"5. Rising Foreign Ownership and a Recent Upgrade\">5. Rising Foreign Ownership and a Recent Upgrade<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/#Pharma_Intermediates_Stock_Financials_Quarterly_Trend\" title=\"Pharma Intermediates Stock Financials: Quarterly Trend\">Pharma Intermediates Stock Financials: Quarterly Trend<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/#Is_This_Pharma_Intermediates_Stock_Expensive\" title=\"Is This Pharma Intermediates Stock Expensive?\">Is This Pharma Intermediates Stock Expensive?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/#Who_Owns_This_Pharma_Intermediates_Stock\" title=\"Who Owns This Pharma Intermediates Stock?\">Who Owns This Pharma Intermediates Stock?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/#Risks_for_This_Pharma_Intermediates_Stock\" title=\"Risks for This Pharma Intermediates Stock\">Risks for This Pharma Intermediates Stock<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/#1_Rich_Valuation\" title=\"1. Rich Valuation\">1. Rich Valuation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/#2_Uneven_Quarterly_Revenue\" title=\"2. Uneven Quarterly Revenue\">2. Uneven Quarterly Revenue<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/#3_Customer_and_Product_Concentration\" title=\"3. Customer and Product Concentration\">3. Customer and Product Concentration<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/#4_Execution_in_Battery_and_Chip_Chemicals\" title=\"4. Execution in Battery and Chip Chemicals\">4. Execution in Battery and Chip Chemicals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/#5_Small-Cap_Liquidity_and_Volatility\" title=\"5. Small-Cap Liquidity and Volatility\">5. Small-Cap Liquidity and Volatility<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/#Acutaas_Chemicals_Share_Analyst_View\" title=\"Acutaas Chemicals Share: Analyst View\">Acutaas Chemicals Share: Analyst View<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/#Acutaas_Chemicals_Share_Price_Target\" title=\"Acutaas Chemicals Share Price Target\">Acutaas Chemicals Share Price Target<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/#Other_Stocks_to_Track_From_the_Same_Return_Screen\" title=\"Other Stocks to Track From the Same Return Screen\">Other Stocks to Track From the Same Return Screen<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/#Which_pharma_intermediates_stock_has_risen_137_in_1_year\" title=\"Which pharma intermediates stock has risen 137% in 1 year?\">Which pharma intermediates stock has risen 137% in 1 year?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/#What_is_the_Acutaas_Chemicals_share_price_today\" title=\"What is the Acutaas Chemicals share price today?\">What is the Acutaas Chemicals share price today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/#Is_Acutaas_Chemicals_the_same_company_as_Ami_Organics\" title=\"Is Acutaas Chemicals the same company as Ami Organics?\">Is Acutaas Chemicals the same company as Ami Organics?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/#Did_Acutaas_Chemicals_split_its_shares\" title=\"Did Acutaas Chemicals split its shares?\">Did Acutaas Chemicals split its shares?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/#What_is_the_Acutaas_Chemicals_share_price_target\" title=\"What is the Acutaas Chemicals share price target?\">What is the Acutaas Chemicals share price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/#Why_did_Acutaas_Chemicals_shares_rise\" title=\"Why did Acutaas Chemicals shares rise?\">Why did Acutaas Chemicals shares rise?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/#What_were_Acutaas_Chemicals_Q1_FY27_results\" title=\"What were Acutaas Chemicals Q1 FY27 results?\">What were Acutaas Chemicals Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/univest.in\/blogs-2\/pharma-intermediates-stock-rises-137-percent-in-1-year\/#What_are_the_main_risks_for_Acutaas_Chemicals\" title=\"What are the main risks for Acutaas Chemicals?\">What are the main risks for Acutaas Chemicals?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"How_Much_Has_This_Pharma_Intermediates_Stock_Gained\"><\/span><strong>How Much Has This Pharma Intermediates Stock Gained?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The pharma intermediates stock rose from a close of Rs 1,458.30 on 10 September 2025 to Rs 3,451.40 on 10 September 2026, a gain of approximately 136.7%. Over the same period, the share traded between a low of Rs 1,302 in late September 2025 and a record Rs 3,740 in July 2026.<\/p>\n<table>\n<thead>\n<tr>\n<th>Period<\/th>\n<th>Return (%)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1 Month<\/td>\n<td>Approximately 5.2%<\/td>\n<\/tr>\n<tr>\n<td>6 Months<\/td>\n<td>Approximately 54.9%<\/td>\n<\/tr>\n<tr>\n<td>1 Year<\/td>\n<td>Approximately 136.7%<\/td>\n<\/tr>\n<tr>\n<td>3 Years<\/td>\n<td>Approximately 419.7%<\/td>\n<\/tr>\n<tr>\n<td>Versus IPO price (Sep 2021, split-adjusted Rs 305)<\/td>\n<td>Approximately 1,031.6%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The company split each Rs 10 share into two shares of Rs 5 with a record date of 25 April 2025. That split falls before the 1-year window, and all older prices above are adjusted for it, so the returns reflect real price movement and not a change in share count.<\/p>\n<p>The pharma intermediates stock listed in September 2021 at an IPO price of Rs 610, which works out to Rs 305 after the split. It hit a record Rs 3,740 in July 2026 and is about 8% below that level now. On 11 September 2026, the pharma intermediates stock was trading around Rs 3,431 in the afternoon.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Did_This_Pharma_Intermediates_Stock_Rise_So_Much\"><\/span><strong>Why Did This Pharma Intermediates Stock Rise So Much?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This pharma intermediates stock rose because earnings grew much faster than sales, margins widened by more than 14 percentage points in a year, and investors began to value new lines such as battery chemicals and contract manufacturing. Each quarterly result in the past year beat the previous year by a wide margin.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"1_Profit_Growth_Far_Ahead_of_Sales_Growth\"><\/span><strong>1. Profit Growth Far Ahead of Sales Growth<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>FY26 revenue from operations rose 33% to approximately Rs 1,339 crore, while profit after tax rose around 122% to Rs 356 crore. EBITDA more than doubled to about Rs 480 crore. The gap came from a richer product mix and fixed costs being spread over a larger sales base.<\/p>\n<p>For a pharma intermediates stock, that kind of margin jump is unusual. Operating EBITDA margin rose to about 35.9% in FY26 from roughly 23% in FY25, and touched 42.4% in the March 2026 quarter.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Quarter_After_Quarter_of_Strong_Results\"><\/span><strong>2. Quarter After Quarter of Strong Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The run began in October 2025, when the September quarter profit rose about 93.5% and the pharma intermediates stock hit a then-record near Rs 1,650. The December quarter followed with profit up about 140% and EBITDA margin of 38.3%, and management raised FY26 growth guidance to 30% from 25%.<\/p>\n<p>The March 2026 quarter was the strongest, with revenue up about 40% and profit up about 114% to around Rs 134 crore. That result pushed the pharma intermediates stock to fresh highs through May and June 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Advanced_Intermediates_and_CDMO_Work\"><\/span><strong>3. Advanced Intermediates and CDMO Work<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The core business behind this pharma intermediates stock makes advanced intermediates used by drug companies to produce active ingredients. This segment formed about 88% of FY26 revenue, and in the June 2026 quarter it grew about 76.5% year on year to around Rs 293 crore.<\/p>\n<p>A growing share of this comes from contract development and manufacturing (CDMO) work for global drugmakers. Management targets CDMO revenue above Rs 1,000 crore by FY28, and says it adds 30 to 40 new molecules to its pipeline each year. This is a large part of why the market now values the pharma intermediates stock at a premium.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"4_Battery_and_Semiconductor_Chemicals\"><\/span><strong>4. Battery and Semiconductor Chemicals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The company behind this pharma intermediates stock has started commercial supply of battery electrolyte additives, which it describes as seeing strong demand under long-term customer contracts. It is also building a plant in South Korea through a joint venture called Indikem to make ultra-pure materials used in chip manufacturing.<\/p>\n<p>The Korea plant is expected to be completed around the end of the March 2027 quarter, with revenue from FY28. These newer lines gave the company a second growth story that pushed it to a record Rs 2,727 in early May 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"5_Rising_Foreign_Ownership_and_a_Recent_Upgrade\"><\/span><strong>5. Rising Foreign Ownership and a Recent Upgrade<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Foreign portfolio investors raised their holding in the pharma intermediates stock from about 16.9% in June 2025 to about 21.6% in June 2026. On 10 September 2026, a domestic brokerage upgraded the pharma intermediates stock to buy, and the share jumped about 6.5% that day on volume roughly five times its recent daily average.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href='https:\/\/univest.in\/screeners'>Check the Univest Screener for Live Fundamentals of High-Return Stocks<\/a><\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Pharma_Intermediates_Stock_Financials_Quarterly_Trend\"><\/span><strong>Pharma Intermediates Stock Financials: Quarterly Trend<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below shows consolidated quarterly figures in Rs crore, with revenue including other income. The March 2026 quarter was the peak, and the June 2026 quarter was lower on a sequential basis but well above the year-earlier level.<\/p>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Revenue<\/th>\n<th>EBITDA<\/th>\n<th>Net Profit<\/th>\n<th>Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Jun 2025<\/td>\n<td>223.18<\/td>\n<td>66.84<\/td>\n<td>44.01<\/td>\n<td>21.37%<\/td>\n<\/tr>\n<tr>\n<td>Sep 2025<\/td>\n<td>316.04<\/td>\n<td>105.16<\/td>\n<td>71.86<\/td>\n<td>23.59%<\/td>\n<\/tr>\n<tr>\n<td>Dec 2025<\/td>\n<td>397.88<\/td>\n<td>155.35<\/td>\n<td>106.22<\/td>\n<td>27.46%<\/td>\n<\/tr>\n<tr>\n<td>Mar 2026<\/td>\n<td>443.86<\/td>\n<td>194.62<\/td>\n<td>134.28<\/td>\n<td>30.45%<\/td>\n<\/tr>\n<tr>\n<td>Jun 2026<\/td>\n<td>331.47<\/td>\n<td>114.87<\/td>\n<td>74.99<\/td>\n<td>22.53%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>In the June 2026 quarter, revenue from operations rose about 59.1% year on year to approximately Rs 330 crore, and profit rose about 70% to around Rs 75 crore. Operating EBITDA margin was 34.3%, up from about 24.6% a year earlier.<\/p>\n<p>Revenue fell about 24% from the March quarter, however, and the pharma intermediates stock dropped about 6% on the day the numbers came out. Management kept its FY27 guidance of approximately 25% revenue growth with EBITDA margin of 32% to 33%, lower than the 35.9% achieved in FY26.<\/p>\n<p>The balance sheet of this pharma intermediates stock is strong. Debt-to-equity stands at about 0.02, equity rose to approximately Rs 1,711 crore in FY26, and operating cash flow was about Rs 292 crore against capital spending of around Rs 328 crore.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Is_This_Pharma_Intermediates_Stock_Expensive\"><\/span><strong>Is This Pharma Intermediates Stock Expensive?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Yes, on current earnings this pharma intermediates stock trades at a large premium. Its trailing PE ratio is approximately 72.95 times, against an industry PE of around 38.02 times.<\/p>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Value<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Market Cap<\/td>\n<td>Approx Rs 28,256 Cr<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio (TTM)<\/td>\n<td>72.95<\/td>\n<\/tr>\n<tr>\n<td>Industry PE<\/td>\n<td>38.02<\/td>\n<\/tr>\n<tr>\n<td>Price to Book<\/td>\n<td>17.09<\/td>\n<\/tr>\n<tr>\n<td>ROE<\/td>\n<td>21.54%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.02<\/td>\n<\/tr>\n<tr>\n<td>Dividend Yield<\/td>\n<td>0.07%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The market is paying for growth that has not yet shown up in the numbers, especially from CDMO, battery and chip chemicals. If those businesses scale as planned, the multiple could come down as earnings rise. If they are delayed, the pharma intermediates stock has little valuation support at these levels.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Who_Owns_This_Pharma_Intermediates_Stock\"><\/span><strong>Who Owns This Pharma Intermediates Stock?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Promoter holding in this pharma intermediates stock has stayed flat at 32.66% for the past five quarters. The main change has been a steady rise in foreign institutional ownership, while domestic institutions trimmed slightly.<\/p>\n<table>\n<thead>\n<tr>\n<th>Holder<\/th>\n<th>Jun 2025<\/th>\n<th>Sep 2025<\/th>\n<th>Dec 2025<\/th>\n<th>Mar 2026<\/th>\n<th>Jun 2026<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Promoters<\/td>\n<td>32.66%<\/td>\n<td>32.66%<\/td>\n<td>32.66%<\/td>\n<td>32.66%<\/td>\n<td>32.66%<\/td>\n<\/tr>\n<tr>\n<td>FII<\/td>\n<td>16.94%<\/td>\n<td>16.85%<\/td>\n<td>16.67%<\/td>\n<td>19.48%<\/td>\n<td>21.61%<\/td>\n<\/tr>\n<tr>\n<td>DII<\/td>\n<td>22.38%<\/td>\n<td>22.59%<\/td>\n<td>21.70%<\/td>\n<td>19.60%<\/td>\n<td>19.56%<\/td>\n<\/tr>\n<tr>\n<td>Public<\/td>\n<td>28.02%<\/td>\n<td>27.91%<\/td>\n<td>28.97%<\/td>\n<td>28.25%<\/td>\n<td>26.17%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>A large sovereign pension fund held about 3.5% as of June 2026, and a multicap mutual fund scheme held a similar stake. The fall in public holding from about 28% to about 26% suggests shares are moving from retail hands to institutions, which often happens as a pharma intermediates stock gains coverage.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Risks_for_This_Pharma_Intermediates_Stock\"><\/span><strong>Risks for This Pharma Intermediates Stock<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The main risks are valuation, lumpy quarterly sales, execution in new businesses and the usual volatility of a small-cap share. Anyone tracking this pharma intermediates stock should weigh these alongside the growth numbers.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"1_Rich_Valuation\"><\/span><strong>1. Rich Valuation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At around 73 times trailing earnings, the stock is priced for strong growth for several years. Any miss on guidance could lead to a sharp fall, as seen when the pharma intermediates stock dropped about 6% after the June 2026 quarter results.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Uneven_Quarterly_Revenue\"><\/span><strong>2. Uneven Quarterly Revenue<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>For a pharma intermediates stock, CDMO orders often come in batches, so revenue can swing sharply between quarters. The drop of about 24% in June quarter revenue from March shows how a single quarter can look weak even within a strong year.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Customer_and_Product_Concentration\"><\/span><strong>3. Customer and Product Concentration<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>A meaningful part of sales is linked to intermediates for a small number of large drugs, including the blood thinner apixaban. Patent expiries, customer inventory cuts or pricing pressure from Chinese suppliers could hurt a pharma intermediates stock with this profile.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"4_Execution_in_Battery_and_Chip_Chemicals\"><\/span><strong>4. Execution in Battery and Chip Chemicals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Korea chip materials plant and the battery electrolyte business are new areas. Delays in plant completion, customer approvals or demand could push revenue beyond FY28 and weaken the growth story behind the Acutaas Chemicals share.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"5_Small-Cap_Liquidity_and_Volatility\"><\/span><strong>5. Small-Cap Liquidity and Volatility<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>As a small-cap pharma intermediates stock, daily trading value is limited, averaging around Rs 82 crore over the three months to June 2026. The share moved between Rs 1,302 and Rs 3,740 in a year and fell about 17% within weeks in late July 2026, so sharp swings in both directions are likely.<\/p>\n<p style=\"margin-top:24px;\"><strong>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track the Acutaas Chemicals share price live<\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Acutaas_Chemicals_Share_Analyst_View\"><\/span><strong>Acutaas Chemicals Share: Analyst View<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Most brokerage coverage on this pharma intermediates stock is positive, but views on price are spread widely because of the high valuation. Analysts mainly point to CDMO growth, margin gains and the new specialty businesses.<\/p>\n<p>A domestic brokerage upgraded the stock to buy from add on 10 September 2026. It expects the CDMO business to grow about 28% a year from FY26 to FY30, and the specialty chemicals segment, including electrolyte additives and chip chemicals, to grow from about Rs 170 crore to Rs 730 crore over the same period. It also sees a recovery in legacy intermediates as the apixaban patent expires in November 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Acutaas_Chemicals_Share_Price_Target\"><\/span><strong>Acutaas Chemicals Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The latest verified Acutaas Chemicals share price target is Rs 3,800 from that domestic brokerage, about 10% above the 10 September close of Rs 3,451.40. Earlier, in March 2026, two domestic brokerages had set targets of Rs 2,350 and Rs 2,501, both of which the stock has since passed.<\/p>\n<p>Across a poll of about 10 analysts, the average Acutaas Chemicals share price target is lower than the current price at around Rs 2,973, with estimates ranging from about Rs 1,423 to Rs 4,001. That spread shows how differently analysts view the pharma intermediates stock at this level.<\/p>\n<p>For reference, the Acutaas Chemicals share price record of Rs 3,740 marks the top of the range, and the 52-week low of Rs 1,302 marks the bottom. Any Acutaas Chemicals share price target is an opinion and can change quickly with results.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Other_Stocks_to_Track_From_the_Same_Return_Screen\"><\/span><strong>Other Stocks to Track From the Same Return Screen<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Beyond this pharma intermediates stock, a screen of 195 small-cap NSE stocks dated 11 September 2026 also includes related names such as <a href=\"https:\/\/univest.in\/stocks\/blissgvs\/bliss-gvs-pharma-ltd-share-price-today\">Bliss GVS<\/a> with a 1-year return of 358.71%, <a href=\"https:\/\/univest.in\/stocks\/shilpamed\/shilpa-medicare-ltd-share-price-today\">Shilpa Medicare<\/a> at 125.18% and <a href=\"https:\/\/univest.in\/stocks\/grwrhitech\/garware-hi-tech-films-ltd-share-price-today\">Garware Hi-Tech Films<\/a> at 107.98%.<\/p>\n<p>Among the names covered from that screen, <a href=\"https:\/\/univest.in\/stocks\/mtartech\/mtar-technologies-ltd-share-price-today\">MTAR Technologies<\/a> returned 396.53% over one year. Readers can compare this pharma intermediates stock with the <a href=\"https:\/\/univest.in\/indices\/nifty-50\/nifty-50-share-price-today\">Nifty 50<\/a> benchmark and track each of these names on Univest before making any decision.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This pharma intermediates stock has returned approximately 137% over one year, driven by profit that more than doubled in FY26, margins that rose to around 36% and a growing CDMO pipeline. New battery and semiconductor chemical lines add a longer-term angle that the market has started to price in.<\/p>\n<p>Against that, the Acutaas Chemicals share price now trades at about 73 times earnings, quarterly revenue can swing sharply, and small-cap volatility has been high. The next few quarters, especially progress on CDMO molecules and the Korea plant, will decide whether this pharma intermediates stock can grow into its valuation.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information and may or may not be accurate. Please verify all data independently before making any investment decision. Past returns do not guarantee future returns. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Which_pharma_intermediates_stock_has_risen_137_in_1_year\"><\/span><strong>Which pharma intermediates stock has risen 137% in 1 year?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Acutaas Chemicals Ltd (NSE: ACUTAAS), formerly Ami Organics, rose approximately 136.7% in one year, from Rs 1,458.30 on 10 September 2025. It closed at Rs 3,451.40 on 10 September 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Acutaas_Chemicals_share_price_today\"><\/span><strong>What is the Acutaas Chemicals share price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The pharma intermediates stock closed at Rs 3,451.40 on 10 September 2026 and traded around Rs 3,431 on 11 September. Its 52-week range is Rs 1,302 to Rs 3,740.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Acutaas_Chemicals_the_same_company_as_Ami_Organics\"><\/span><strong>Is Acutaas Chemicals the same company as Ami Organics?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Yes. Ami Organics Ltd, the pharma intermediates stock, changed its name to Acutaas Chemicals Ltd with effect from 15 May 2025, and the NSE symbol changed to ACUTAAS. The business and management remain the same.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Did_Acutaas_Chemicals_split_its_shares\"><\/span><strong>Did Acutaas Chemicals split its shares?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Yes. Each Rs 10 share was split into two shares of Rs 5 with a record date of 25 April 2025. This happened before the 1-year window, so the 1-year return of about 137% is not affected by the split.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Acutaas_Chemicals_share_price_target\"><\/span><strong>What is the Acutaas Chemicals share price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> A domestic brokerage set a Rs 3,800 target on the stock on 10 September 2026 with a buy rating. The average of about 10 analysts is around Rs 2,973, below the current price.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_did_Acutaas_Chemicals_shares_rise\"><\/span><strong>Why did Acutaas Chemicals shares rise?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> FY26 profit rose about 122% to Rs 356 crore on 33% revenue growth, with EBITDA margin rising to about 35.9%. Growth in CDMO work at the pharma intermediates stock, new battery chemicals and a planned chip materials plant in Korea also lifted investor interest.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_Acutaas_Chemicals_Q1_FY27_results\"><\/span><strong>What were Acutaas Chemicals Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> In the June 2026 quarter, revenue from operations rose about 59.1% year on year to around Rs 330 crore, and profit rose about 70% to around Rs 75 crore. Revenue was about 24% lower than the March quarter.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_risks_for_Acutaas_Chemicals\"><\/span><strong>What are the main risks for Acutaas Chemicals?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The key risks for this pharma intermediates stock are a PE of about 73 times, uneven quarterly revenue, reliance on a few large drug intermediates, execution risk in new businesses and small-cap volatility. The stock has swung between Rs 1,302 and Rs 3,740 in a year.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Which pharma intermediates stock has risen 137% in 1 year?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Acutaas Chemicals Ltd (NSE: ACUTAAS), formerly Ami Organics, rose approximately 136.7% in one year, from Rs 1,458.30 on 10 September 2025. It closed at Rs 3,451.40 on 10 September 2026.\"}},{\"@type\":\"Question\",\"name\":\"What is the Acutaas Chemicals share price today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The pharma intermediates stock closed at Rs 3,451.40 on 10 September 2026 and traded around Rs 3,431 on 11 September. Its 52-week range is Rs 1,302 to Rs 3,740.\"}},{\"@type\":\"Question\",\"name\":\"Is Acutaas Chemicals the same company as Ami Organics?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Yes. Ami Organics Ltd, the pharma intermediates stock, changed its name to Acutaas Chemicals Ltd with effect from 15 May 2025, and the NSE symbol changed to ACUTAAS. The business and management remain the same.\"}},{\"@type\":\"Question\",\"name\":\"Did Acutaas Chemicals split its shares?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Yes. Each Rs 10 share was split into two shares of Rs 5 with a record date of 25 April 2025. This happened before the 1-year window, so the 1-year return of about 137% is not affected by the split.\"}},{\"@type\":\"Question\",\"name\":\"What is the Acutaas Chemicals share price target?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"A domestic brokerage set a Rs 3,800 target on the stock on 10 September 2026 with a buy rating. The average of about 10 analysts is around Rs 2,973, below the current price.\"}},{\"@type\":\"Question\",\"name\":\"Why did Acutaas Chemicals shares rise?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"FY26 profit rose about 122% to Rs 356 crore on 33% revenue growth, with EBITDA margin rising to about 35.9%. Growth in CDMO work at the pharma intermediates stock, new battery chemicals and a planned chip materials plant in Korea also lifted investor interest.\"}},{\"@type\":\"Question\",\"name\":\"What were Acutaas Chemicals Q1 FY27 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"In the June 2026 quarter, revenue from operations rose about 59.1% year on year to around Rs 330 crore, and profit rose about 70% to around Rs 75 crore. Revenue was about 24% lower than the March quarter.\"}},{\"@type\":\"Question\",\"name\":\"What are the main risks for Acutaas Chemicals?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The key risks for this pharma intermediates stock are a PE of about 73 times, uneven quarterly revenue, reliance on a few large drug intermediates, execution risk in new businesses and small-cap volatility. The stock has swung between Rs 1,302 and Rs 3,740 in a year.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>A small-cap maker of advanced drug intermediates has gained around 137% in a year as profit more than doubled. Here is what drove the rally and what could slow it.<\/p>\n","protected":false},"author":29,"featured_media":244152,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[],"class_list":["post-244155","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["244152"],"rank_math_title":["Pharma Intermediates Stock Up 137% in 1 Year: Drivers, Risks"],"rank_math_description":["This pharma intermediates stock rose around 137% in 1 year as FY26 profit more than doubled. See Q1 FY27 results, valuation, shareholding, targets and key risks."],"rank_math_focus_keyword":["pharma intermediates stock"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/09\/pharma-intermediates-stock-rises-137-percent-in-1-year.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/244155","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=244155"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/244155\/revisions"}],"predecessor-version":[{"id":244157,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/244155\/revisions\/244157"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/244152"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=244155"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=244155"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=244155"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}